Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort
Previous clinical studies had not shown expected results in advanced pancreatic cancer (APC) with single-agent checkpoint inhibitors. Until the present day, little is known about their performance in real-world settings. So, in this study, we investigate the ICIs' efficacy and safety in Chinese...
Saved in:
Main Authors: | Xiaoling Gong (Author), Yahui Zhu (Author), Qianning Zhang (Author), Xin Qiu (Author), Changchang Lu (Author), Fan Tong (Author), Qiaoli Wang (Author), Weiwei Kong (Author), Haihui Zhou (Author), Baorui Liu (Author), Yujie Zhou (Author), Juan Du (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
by: Xin Qiu, et al.
Published: (2023) -
Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort
by: Sun D, et al.
Published: (2018) -
Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
by: Na Li, et al.
Published: (2023) -
Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data
by: Yanna Lei, et al.
Published: (2022) -
Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis
by: Tian Zhang, et al.
Published: (2022)